AveXis, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AveXis, Inc. - overview
Established
2010
Location
Bannockburn, IL, US
Primary Industry
Biotechnology
About
AveXis, Inc. is a biotechnology company focused on developing innovative gene therapies for the treatment of rare neurological diseases, aiming to transform patient care and improve quality of life. Founded in 2010 in Bannockburn, US, AveXis specializes in gene therapy solutions for spinal muscular atrophy and other conditions. In February 2016, the company raised USD 95 mn by offering shares.
In April 2018, Novartis AG acquired AveXis for USD 8. 7 bn. Doris Philips serves as CEO. AveXis develops gene therapies targeting severe neurological disorders, including its flagship product Zolgensma®, designed for spinal muscular atrophy.
These therapies are distributed globally and aim to address critical health challenges, improving care for patients with complex medical needs. In 2017, AveXis reported a revenue of USD 0, with an EBITDA of USD -218,097,000. AveXis plans to expand its product portfolio with upcoming gene therapies targeting additional rare diseases. The company intends to penetrate new markets in Europe and Asia by 2020.
The recent acquisition by Novartis will enhance its capabilities to fund these initiatives, ensuring broader access to its innovative therapies.
Current Investors
Roche Venture Fund, Deerfield Management
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Healthcare
Website
www.avexis.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.